No abstract available.
Lung* ; Thorax*

BACKGROUND: Atopic dermatitis is a global public health concern owing to its increasing prevalence and socioeconomic burden. However, few studies have assessed the economic impact of atopic dermatitis in Korea. OBJECTIVE: We conducted a cost analysis of atopic dermatitis and evaluated its economic impacts on individual annual disease burden, quality of life, and changes in medical expenses with respect to changes in health related-quality of life. METHODS: The cost analysis of atopic dermatitis was performed by reviewing the home accounting records of 32 patients. The economic impact of the disease was evaluated by analyzing questionnaires. To handle uncertainties, we compared the results with the data released by the Health Insurance Review & Assessment Board on medical costs claimed by healthcare facilities. RESULTS: The direct cost of atopic dermatitis per patient during the 3-month study period was 541,280 Korean won (KRW), and expenditures on other atopic dermatitis-related products were 120,313 KRW. The extrapolated annual direct cost (including expenditures on other atopic dermatitis-related products) per patient was 2,646,372 KRW. The estimated annual indirect cost was 1,507,068 KRW. Thus, the annual cost of illness of atopic dermatitis (i.e., direct+indirect costs) was estimated to be 4,153,440 KRW. CONCLUSION: The annual total social cost of atopic dermatitis on a national level is estimated to be 5.8 trillion KRW.
Cost of Illness ; Costs and Cost Analysis ; Delivery of Health Care ; Dermatitis, Atopic* ; Health Expenditures ; Humans ; Insurance, Health ; Korea ; Prevalence ; Public Health ; Quality of Life ; Surveys and Questionnaires

PURPOSE: Shorter response time is very important for critically-ill patients. The study utilized a linear planning and simulation technique to design a two-tiered system with advanced life support (ALS) ambulances. METHODS: We collected the ambulance run-sheet data from a fire department from January, 2006 to December, 2007 to determine emergency medical service (EMS) demands. The location of patient ambulance stations were mapped by geocoding and the most appropriate number and location of ambulances was calculated with the linear planning method. The planning result was validated with a discrete simulation. RESULTS: The initial enrollment was 227,377 cases of 119 calls. After geocoding, 170,472 (74.9%) cases were directly matched, 56,899 (25.0%) were indirectly matched, and (0.1%) were not matched. The latter were excluded. Using the linear planning method, the number of additional ambulances was calculated for a new two-tiered ambulance system that could achieve a 90% service level. From the current single-tiered system with 112 ambulances to a two-tiered system of 211 basic life support (BLS) units and 40 ALS units, the BLS service level for minor patients could be raised to 90%. For severely-ill patients , a BLS and ALS service level of up to 82% and 89%, respectively, service level could be achieved. The new two-tiered system was validated with the discrete simulation. After the simulation, the BLS and ALS service level for severely-ill patients reached 85% and 93%, respectively. As well, a 100% BLS service level for minor patients was achieved. CONCLUSION: Linear planning and discrete simulation with GIS data enabled the simulation of a two-tiered ambulance system that can shorten the response time of the current single-tiered system.
Advanced Cardiac Life Support ; Ambulances ; Emergencies ; Emergency Medical Services ; Fires ; Geographic Mapping ; Humans ; Reaction Time

PURPOSE: There is no standard method for confirming the immunogenicity of acellular pertussis vaccines. We tried to develop a local standard method for evaluating the immunogenicity of the three-component of acellular pertussis vaccines which was developed by a Korean local company. MATERIALS AND METHODS: The developed pertussis antigens (pertussis toxin, filamentous hemagglutinin, pertactin) were evaluated by in-house enzyme-linked immunosorbent assay (ELISA) using 189 negative sera, 25 positive sera, and 73 paired sera (pre- and post-Tdap [tetanus, diphtheria, and acellular pertussis] vaccinated sera). ELISA units were calculated by the reference line method, compared with World Health Organization reference sera, and the cut-off value was calculated using negative sera. RESULTS: When compared to National Institute for Biological Standards and Control control antigen (NIBSC) control antigens, the developed pertussis toxin (PT) and filamentous haemagglutinin (FHA) antigens were 203.48 and 61.60 IU/µg, respectively. Each in-house ELISA was established by validating the coefficients of variation % (PT, 11.53%; FHA, 8.60%; pertactin [PRN], 9.86%) obtained from the results of inter- and intra-assay variation. Also, the cut-off values of PT, FHA, and PRN were 11.65, 38.95, and 5.66 EU/mL, respectively. The distributions of antibody levels in paired showed that 93.15% (68/73) in anti-PT IgG, 97.26% (72/73) in anti-FHA IgG, and 100% in anti-PRN IgG were higher than a 100% increase after vaccination. Additionally, the values of 89.04% (65/73) in anti-PT IgG, 97.26% (72/73) in anti-FHA IgG, and 100% in anti-PRN IgG were below each cut-off point. CONCLUSION: We established an in-house ELISA method using self-developed antigens, and these immunoassays have provided a way to standardize measuring the immunogenicity of newly developed vaccines, through single- and dual-serology.
Diphtheria ; Enzyme-Linked Immunosorbent Assay ; Hemagglutinins ; Immunoassay ; Immunoglobulin G ; Korea* ; Methods* ; Pertussis Toxin ; Pertussis Vaccine ; Vaccination ; Vaccines* ; Whooping Cough* ; World Health Organization